Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Operating Officer

President

Chief Financial Officer

Chief Medical Officer

General Counsel

Chief Executive Officer

Chief Accounting Officer

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-27	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-02-27	Premium	sold	Premium	Premium	Premium	President
2024-02-27	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-02-26	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-02-26	Premium	sold	Premium	Premium	Premium	President
2024-01-29	Premium	bought	Premium	Premium	Premium	-
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	President
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-01-02	Premium	sold	Premium	Premium	Premium	President
2024-01-02	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-29	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2023-12-20	Premium	back to issuer	Premium	Premium	Premium	Chief Accounting Officer
2023-12-19	Premium	back to issuer	Premium	Premium	Premium	President
2023-12-19	Premium	back to issuer	Premium	Premium	Premium	General Counsel
2023-12-19	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2023-12-19	Premium	back to issuer	Premium	Premium	Premium	Chief Medical Officer
2023-12-19	Premium	back to issuer	Premium	Premium	Premium	Chief Accounting Officer

RCUS - Arcus Biosciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RCUS